Introduction
Humans display variation in immune responses to vaccination with defined antigens at individual and population levels. Several human vaccines have well illustrated the variability in immune responses among human populations. The efficacy of Bacille Calmette-Gué rin (BCG), perhaps the worlds most widely used vaccine, varied significantly between studies, with a significant fraction of that variation being explained by geographic location (latitude) [1, 2] . Similarly, the immunogenicity of candidate cholera vaccines was more than 90% among North American and European adult volunteers [3] , and protective efficacy in challenge studies was commensurately high [4] . Yet in endemic areas, the CVD103-HgR vaccine yielded poor immunogenicity and poor levels of protective efficacy in field trials [5] .
Defining the possible sources of such variation is useful for modifying therapy in relation to individual characteristics. Anticipating variation in response to vaccination is also relevant to the design of clinical trials to evaluate new vaccines. Trial eligibility criteria may be modified to address some of these cofactors. Vaccine formulation with adjuvants or incorporating a broader range of antigens in a novel vaccine may be other responses to deal with response variation. Few of the many potential influences have been examined within the context of HIV vaccine clinical trials. Clinical trials of candidate HIV vaccines have thus generally addressed known cofactors in defining trial eligibility among low-and high-risk populations.
The review will not deal with vaccine regimen issues such as dose, vaccination schedule, or route of delivery, nor with the role of adjuvants -the latter is dealt with elsewhere in this issue -nor with prediction of adverse responses to vaccination. In this overview, I will focus on new developments in the understanding and role of some of these vaccine response cofactors (given below):
Selected factors that may influence responses to candidate HIV vaccines:
(1) Demographic and patient characteristics (a) age (b) sex (c) race/ethnicity (d) geographic location
Purpose of review
This review summarizes recent developments related to cofactors that may influence response to vaccination.
Recent findings
The unexpected increased HIV acquisition among vaccinees in the Step trial with prior exposure to adenovirus type 5 (Ad5) led to several studies trying to understand whether an underlying biological risk factor may have been responsible for this observation. Demographic factors and genetic background of the human populations in HIV vaccine trials remain a source of potential variation in responses observed in vaccine trials, yet empirical data remain limited on the impact of those factors. Coinfections, particularly those that may modulate the immune response, are a further concern for HIV vaccine trialists, with recent data providing further insight into effects of coinfections on innate and adaptive immunity and vaccine responses. Summary Individuals and human populations display variation in response to vaccination. Key explanatory variables for this variation include host factors, such as host genetics, and environmental factors, such as prior exposure to the vaccine vector, coinfection with other pathogens, and demographic factors. This review will outline some of the recent developments investigating the role of various cofactors on vaccine responses, with a particular emphasis on studies of HIV vaccines. In recent trials of candidate HIV vaccines, a key cofactor has been pre-existing immunity to the vaccine vector. This important topic is also dealt with in other contributions to this edition.
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Pre-existing immunity to vaccine vectors
Reduction in vaccine effectiveness due to pre-existing immunity to vaccine vectors is a well described limitation of the vector-based approach [6] [7] [8] [9] . This factor is the key rationale for development of alternative vectors to which human populations have limited prior exposure, as described elsewhere in this edition [10] .
An unanticipated finding of the Step trial was the increased rate of HIV acquisition among vaccinees seropositive for adenovirus 5 (Ad5) compared to placebo recipients [11, 12] . Whereas it remains unclear whether a biological explanation was responsible for this finding, the observation stimulated close examination of this question. Several hypotheses were advanced to explain the increased rate of HIV acquisition, as outlined elsewhere [13] : the Ad5 vector boosted pre-existing vectorspecific T-cell immunity, which resulted in increased numbers of activated target cells, and thereby an increased susceptibility to infection, given exposure; prior adenovirus exposure to natural infection may have resulted in responses primarily directed to mucosal responses and boosting of these pre-existing responses by the vector may have resulted in greater concentration of activated T cells at mucosal surfaces; vaccination may have resulted in generation of antibodies that may have enhanced HIV acquisition.
Subsequent analyses have cast doubts on the tenability of at the least the first of these proposed mechanisms. Hutnick and colleagues [14 ] studied the Ad5-specific T-cell responses following vaccination with an earlier prototype of the Step vaccine, and found that both Ad5-seronegative and -seropositive individuals had detectable Ad5-specific CD4 þ T-cell responses, of similar magnitude. Moreover, the Ad5-neutralizing anti-body titres did not correlate with Ad5-specific CD4þ T-cell frequencies. Following vaccination, CD4þ T-cell responses expanded in both baseline Ad5-seropositive and seronegative vaccinees. Ad5 NAbs developed in all baseline Ad-seronegative vaccinees by week 8 following first vaccination. There were no observed differences in magnitude of T-cell responses between vaccinees and placebo recipients that may support vector-induced CD4 T-cell expansion as the mechanism for the Step results.
Other investigators have reported that vector-antibody immune complexes may have led to effects on dendritic cells, such as promotion of dendritic cell maturation, and higher levels of HIV replication in cell cultures following Ad5-immune complex stimulation of dendritic cells [15] . The true relevance of these experimental findings to the interpretation of the Step and Phambili results remain uncertain and await analysis of final follow-up of study volunteers.
Koup and colleagues [16] reported that, following administration of an Ad5 vector containing deletions in the adenovirus E1, E3, and E4 genes, no expansion of vectorspecific CD4 þ T cells was detectable. This finding would support continued examination of adenovirus-vectored vaccines, particularly among adenovirus-seronegative individuals, and possibly favour vaccines containing multiple gene deletions.
It also appears important to consider the role of nonhuman primate studies compared to human trials when considering the unanticipated nature of the Step result. Preclinical nonhuman primate or mouse studies of vectorbased approaches may yield important data, yet cannot fully elucidate all of the relevant biology. For example, mice and nonhuman primates such as rhesus macaques are nonpermissive for human adenovirus replication. Animal models have typically induced 'pre-existing immunity' by immunization with adenovirus vectors bearing alternative antigens [8, 17] . As these vectors are delivered by an alternative route to natural infection, and are delivered to a nonpermissive host, this 'pre-existing immunity' is likely to be associated with differences in the type and quality of immune responses induced. This factor would, in turn, impact on the findings if animals receive a viral challenge. An examination of human antibody specificity elicited by natural infection or vaccination demonstrated that natural infection is associated with antibodies directed to the Ad5 fibre, whereas antibodies elicited by vaccination were mainly directed to nonfibre capsid proteins [18 ] .
Demographic and other characteristics
Certain individual demographic characteristics are well known to be associated with vaccine immunogenicity or efficacy, such as age or sex [19] [20] [21] [22] . Analysis of HIV vaccine clinical trial data for such associations has been limited. In response to claims of efficacy in certain race/ ethnicity groups in the first phase III trial of AIDSVAX B/B [23] , data from NIH-funded trials of similar vaccine candidates was analysed to determine whether similar patterns of responses were noted among race/ethnicity subgroups [24] . In this analysis, age was not an influential factor, when dividing participants into 18-35 and 36-59-year age strata. When examining responses to gp120 vaccines, sex did not influence geometric mean titres (GMTs) of neutralizing antibody responses, whereas race/ethnicity did. Among those studies, African American participants had GMTs 2.6-4.7-fold higher than white participants. Trials of ALVAC vectors with gp120 or ALVAC alone did not demonstrate any differences in neutralizing antibody responses by sex or race/ ethnicity.
In other recent studies, age was a major modifying factor. Among five trials of quadrivalent human papillomavirus vaccine (HPV) given at 0, 2, and 6 months to male and female participants between 9 and 23 years of age, titres of antibodies to each HPV type decreased with increasing age [25] . The authors report that, after adjusting for age, no baseline characteristics consistently predicted antibody response titres to each of the four HPV types in multivariate analyses. For individual types, some characteristics were significant, including body mass index (BMI), race/ethnicity, and location. In addition, antibody titres were noted to be generally higher among male participants than female participants. No effect of smoking or contraceptive use was noted in these trials.
Genetic factors
Multiple cellular mechanisms are required for the immune system to generate an immune response to vaccination. From cell entry and replication (in the case of vectored vaccines) to pathogen recognition to antigen uptake and processing to B-and T-cell function and so on, each is associated with polymorphic host genes [26] . The heritability component of vaccine-induced immune responses also varies for different vaccines. Studies of monozygotic and dizygotic twins have been valuable in providing a quantitative estimate of the heritability contribution. Studies from The Gambia have illustrated that, among infants, antibody responses to hepatitis B virus (HBV) show heritability of 77%, oral polio vaccine 60%, tetanus toxoid 44%, diphtheria 49%, and Haemophilus influenzae b 51% [27, 28] . Among adults and older children, hepatitis B and measles response have been best studied. It is estimated that, for hepatitis B, heritability of the immune response is 61%, with approximately 40% being determined by human leukocyte antigen (HLA)-encoded factors, and the majority by genes outside of the major histocompatibility complex (MHC) [29] .
Among the identified human genetic factors associated with HIV control, HLA haplotype accounts for much of the explained human variation [30, 31] . As has been noted for other cofactors, few studies have as yet been reported that describe the role of either candidate genes or common genetic variation on vaccine responses to HIV vaccines. Prior work examining genetic factors predictive of responses to ALVAC demonstrated that individuals bearing HLA-B27 or HLA-B57 had a high response frequency than individuals without those alleles [32] . These same alleles are associated with slower progression to AIDS among HIV-infected individuals. Further analyses from the Thai prime-boost and Step trial are eagerly awaited for what those studies can contribute to an understanding of this area.
Coexisting conditions or infections
Many viral, bacterial, and parasitic pathogens have effects on the human immune system that could affect responses to vaccination. Among viruses, HIV [33] [34] [35] , HBV [36] , cytomegalovirus (CMV) [37] , and measles virus [38] are but a few that are known to impact immune responses. Thus, clinical trials of candidate HIV vaccines exclude participants with known HIV infection, chronic hepatitis, and acute medical illnesses.
Parasitic infections too have modulatory effects on the human immune system. These effects have been proposed as underlying the global patterns of allergic and autoimmune diseases. Experimental evidence also supports the ability of parasitic infestation to alter human immune responses to bystander antigens, such as in the setting of vaccination. These alterations are also manifest in clinical laboratory reference ranges for certain analytes, as recently shown in studies to define locally appropriate reference ranges for use in international clinical trials [39, 40] .
Helminths use several approaches to modulate the immune response [41] . Broadly, helminth infections induce strong T helper 2 (Th2) responses. In addition, helminth infections induce regulatory T cells, antiinflammatory cytokines, and other mechanisms. Specific helminth-derived products have been characterized as having immunomodulatory effects, including lysophosphatidylserine [42] , phosphatidylserine [43] , lacto-Nfucopentaose III [44] , Acanthocheilonema viteae ES62 [45, 46] , Schistosoma mansoni dsRNA [47] , cathepsin cysteine proteases [48] , and others. These products may have effects that function via interactions with Toll-like receptors (TLRs), including TLR-2, -3, or -4 in particular, or impact TLR-signalling pathways. Certain immunomodulatory effects may also function vial TLRindependent mechanisms.
Supportive data on the impact of parasitic coinfections from HIV vaccine clinical trials remain limited. A recent study demonstrated an impairment in vaccine-induced T-cell responses by coexisting infection with S. mansoni in a mouse model [49] . Treatment of the helminth infection with praziquantel prior to vaccination was associated with improved immune responses, compared to responses among persistently infected mice. A timedependent improvement in responses was also apparent, with CD8 responses among mice immunized at 4 weeks following praziquantel treatment being inferior to naïve mice. Responses were essentially equivalent if the immunization series was initiated at eight weeks following treatment.
Studies addressing immunomodulatory effects to other antigens have raised other potentially important impacts of parasitic coinfections. A study among patients with symptomatic Vibrio cholerae infection in Bangladesh examined the impact of parasitic coinfection on development of immune responses to cholera infection [50] . Symptomatic V. cholerae infection typically leads to development of protective immunity with both humoral and mucosal immune responses. Coinfection with helminths among cholera patients led to reduced mucosal immune responses to an immunodominant cholera antigen, cholera toxin B (CTB).
Route of exposure
In both the Step and Phambili trials, the incidence of HIV varied considerably by route of exposure [11] . The risk of HIV acquisition is known to vary according to sex [51] , route of exposure [51] , coexistence of genital tract infections [52] [53] [54] , viral load in the source partner [55] , male circumcision status [56] , and possibly other factors [57, 58] . Immune protection against HIV may well require that candidate HIV vaccines be able to elicit immune responses at mucosal sites. To the extent that mucosal responses may be better elicited at some sites, differential efficacy according to varying routes of exposure may be observed. Similarly, even if immune responses are efficiently induced at all relevant route of exposure, differential efficiency of transmission via those routes may still yield differential vaccine efficacy. Whereas these are still theoretical concerns for HIV vaccines, future trials will need to consider the potential for differential efficacy by route of exposure.
Conclusion
The range of cofactors that can influence human immune responses to vaccination is vast, and include both host and environmental factors. In the context of HIV vaccine development, few of these factors have been examined in any detail. Recent clinical trial results have highlighted the importance of gaining a better understanding of prior exposure to vaccine vectors. Future studies should also address the impact of socioeconomic factors, host genetics, and other environmental exposures on modifying vaccine responses.
